The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | The impact of daratumumab induction on stem cell collection in myeloma patients
Natalie Callander, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI, briefly compares stem cell collection in the MASTER trial (NCT03224507) versus the GRIFFIN trial (NCT02874742) with the aim of evaluating the impact of daratumumab induction on stem cell collection for transplant. Dr Callander explains that whether granulocyte colony-stimulating factor (G-CSF) was used with plerixafor automatically or as rescue plerixafor, there was no negative impact of daratumumab on the ability to collect stem cells. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
